» Articles » PMID: 6744360

Effects of Sotalol on Arrhythmias and Electrophysiology During Myocardial Ischaemia and Reperfusion

Overview
Journal Cardiovasc Res
Date 1984 Jul 1
PMID 6744360
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Isolated, buffer perfused guinea pig hearts were used to study the effects of sotalol on arrhythmias and electrophysiology during 30 min of myocardial ischaemia, induced by reducing coronary flow to 10% of control, and subsequent reperfusion. Action potentials were recorded using the floating microelectrode technique and arrhythmias were noted and defined by extracellular electrical records. Sotalol 10(-4) mol X litre-1 reduced the incidence of ventricular arrhythmias during myocardial ischaemia and reperfusion. Prior to the onset of ischaemia sotalol reduced action potential amplitude and Vmax, and prolonged action potential duration, refractory period, and conduction time, and increased pacing threshold. During myocardial ischaemia the effect of sotalol on action potential duration disappeared, and that on refractory period was diminished. The effect of sotalol on action potential amplitude and Vmax was reduced during the early (2 to 12 min) part of ischaemia, but later, at the onset of arrhythmias, tended to reemerge, while the effect on QRS width was exaggerated. Thus the cellular electrophysiological effects of sotalol on normal myocardium provided a poor guide to the mechanism of its antiarrhythmic action in ischaemic tissue.

Citing Articles

RSD1019 suppresses ischaemia-induced monophasic action potential shortening and arrhythmias in anaesthetized rabbits.

Barrett T, MacLeod B, Walker M Br J Pharmacol. 2000; 131(3):405-14.

PMID: 11015289 PMC: 1572350. DOI: 10.1038/sj.bjp.0703592.


Repolarisation and refractoriness during early ischaemia in humans.

Sutton P, Taggart P, Opthof T, Coronel R, Trimlett R, Pugsley W Heart. 2000; 84(4):365-9.

PMID: 10995401 PMC: 1729435. DOI: 10.1136/heart.84.4.365.


Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Fitton A, Sorkin E Drugs. 1993; 46(4):678-719.

PMID: 7506652 DOI: 10.2165/00003495-199346040-00007.


Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Singh B, Deedwania P, Nademanee K, Ward A, Sorkin E Drugs. 1987; 34(3):311-49.

PMID: 3315621 DOI: 10.2165/00003495-198734030-00002.


Class III antiarrhythmic drugs (amiodarone, bretylium and sotalol) on action potentials and membrane currents in rabbit sino-atrial node preparations.

Satoh H Naunyn Schmiedebergs Arch Pharmacol. 1991; 344(6):674-81.

PMID: 1775200 DOI: 10.1007/BF00174751.